在 COVID-19 大流行期间使用羟氯喹和氯喹：每个临床医生都应该知道的事。
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
机构信息
Zuckerberg San Francisco General Hospital, University of California, San Francisco, California (J.Y.).
Washington University School of Medicine, St. Louis, Missouri (A.H.K.).
出版信息
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
Abstract
Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest as potential therapies for coronavirus disease 2019. The authors of this commentary provide guidance for clinical decision making for patients with coronavirus disease 2019 as well as for patients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis
摘要
两种常用于治疗免疫介导性疾病的药物，羟氯喹和氯喹，最近作为新型冠状病毒病 2019 的潜在疗法引起了广泛关注。本文作者就新型冠状病毒病 2019 患者以及系统性红斑狼疮和类风湿关节炎等风湿性疾病患者的临床决策提供了指导。
相似文献
1
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
2
Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Nat Med. 2020 May;26(5):632. doi: 10.1038/s41591-020-0853-0.
3
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
Drug Discov Today. 2020 Jul;25(7):1121-1123. doi: 10.1016/j.drudis.2020.04.021. Epub 2020 May 1.
4
Drug Evaluation during the Covid-19 Pandemic.
N Engl J Med. 2020 Jun 11;382(24):2282-2284. doi: 10.1056/NEJMp2009457. Epub 2020 Apr 14.
5
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
Am J Trop Med Hyg. 2020 May;102(5):932-933. doi: 10.4269/ajtmh.20-0230.
6
Regulators split on antimalarials for COVID-19.
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
7
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
J Coll Physicians Surg Pak. 2020 Oct;30(10):124-128. doi: 10.29271/jcpsp.2020.supp2.124.
8
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
Kardiol Pol. 2020 Aug 25;78(7-8):811-817. doi: 10.33963/KP.15511. Epub 2020 Jul 14.
9
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
10
Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Biomedica. 2020 Oct 30;40(Supl. 2):80-95. doi: 10.7705/biomedica.5478.
引用本文的文献
1
Potential Therapeutic Options for COVID-19.
Infect Microbes Dis. 2020 Jul 16;2(3):89-95. doi: 10.1097/IM9.0000000000000033. eCollection 2020 Sep.
2
Chloroquine: A Potential Drug in the COVID-19 Scenario.
Trans Indian Natl Acad Eng. 2020;5(2):399-410. doi: 10.1007/s41403-020-00114-w. Epub 2020 Jun 7.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
A review: Mechanism and prospect of gastrodin in prevention and treatment of T2DM and COVID-19.
Heliyon. 2023 Oct 26;9(11):e21218. doi: 10.1016/j.heliyon.2023.e21218. eCollection 2023 Nov.
5
Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.
Ann Pharmacother. 2024 Jul;58(7):742-755. doi: 10.1177/10600280231204969. Epub 2023 Oct 26.
6
Impact of prophylactic hydroxychloroquine on ultrastructural impairment and cellular SARS-CoV-2 infection in different cells of bronchoalveolar lavage fluids of COVID-19 patients.
Sci Rep. 2023 Aug 5;13(1):12733. doi: 10.1038/s41598-023-39941-6.
7
Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.
Molecules. 2023 May 12;28(10):4045. doi: 10.3390/molecules28104045.
8
Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and Warning Letters From Food and Drug Administration: Content Analysis and Identification.
JMIR Infodemiology. 2023 Jan 23;3:e38390. doi: 10.2196/38390. eCollection 2023.
9
The immunomodulatory properties of low-level ionizing radiation as a potential treatment for COVID-19's life-threatening symptoms.
Eur J Med Res. 2023 Feb 11;28(1):73. doi: 10.1186/s40001-023-00999-7.
10
COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats.
Physiol Rep. 2023 Feb;11(3):e15598. doi: 10.14814/phy2.15598.
本文引用的文献
1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
5
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
6
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7.
7
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.
Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5.
8
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Arthritis Rheum. 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156.
9
In vitro inhibition of human influenza A virus replication by chloroquine.
Virol J. 2006 May 29;3:39. doi: 10.1186/1743-422X-3-39.
10
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
N Engl J Med. 1991 Jan 17;324(3):150-4. doi: 10.1056/NEJM199101173240303.
Zotero 插件